Clinical Trial Update: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. [Phase 3]

View source ↗

Summary

This entry notes an open-label Phase 3 clinical trial evaluating Lutetium-177 Lu oxodotreotide for advanced gastroenteropancreatic neuroendocrine tumors, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 Lu oxodotreotide (Lutetium-177 dotatate)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Status: RECRUITING